Efficacy And Of Simvastatin On Overweight Patients With Asthma

Background and purposeIn recent years,with the change of the modern way of life and the environment,community health care in obesity related diseases incidence increased year by year,such as high blood pressure,diabetes and bronchial asthma.Obese patients with asthma in clinical work have poor sensitivity to conventional drugs,less asthma symptoms,and difficult to control,and badly need to develop targeted drugs.In recent years,many studies have shown that statins what commonly used in reduce blood fat,in addition to regulating cholesterol metabolism,but also hasanti-inflammatory,inhibition of smooth muscle hyperplasia and immunity inhibition,might be provide new ideas for the treatment ofbronchial asthma,especially obesity asthmas which is resistance to glucocorticoids.From clinical,this study adopts randomized controlled study to evaluate the clinical curative effect and safety of simvastatin in the treatment of obese patients with asthma,and through the change of blood leptin level to explore its effectiveness.Methods1、40 patients with obese asthma enrolled from ten community clinics in Qingdao from January 2015 to June 2015 were randomly divided into 2 groups,the experimental group and the conventional group.The conventional group was treated with regular therapy based on the asthma guideline,and the experimental group was received simvastatin 20 mg QD in addition to the regular treatment as conventional group.The study was 8 weeks,one visit every 4 weeks,a total of 3 visits:V1、V2、V3.2 、 In the study period,all patients have been required to record the symptom scores(daytime symptom,night symptom),the use of rescue drugs,and the adverse events every day for 8 weeks.The ACT scores and spirometry were evaluated,as well as,serum AST andserum ALT were tested at V1,V2,V3.At the end of the V3 measured the serum leptin levels which was collected in V1 and V3.3、After the research,compare the change of all the above-mentioned indicators of the two groups,to evaluate the effect and security of simvastatin in the treatment of obesity asthma.Results1、All patients were successfully completed the test,without lost,exit and deaths.2、At V2,V3,the daytime symptoms [(1.30 ± 0.47)/d,(1.26 ± 0.44)/d],the night symptom [(1.35 ± 0.49)/d,(1.30 ± 0.47)/d],the torin usage [(1.10 ±0.64)/d,(0.65 ±0.60)/d],the ACT scores [(20.05± 3.38),(22.60-2.39)],and FVC [(2.56 ±0.63)L,(2.87± 0.47)L] of theexperimental group were improved significantly than V1(1.85 ±0.81)/d,(1.90±0.79)/d,(1.60± 0.82)/d,(16.80±2.93),(2.27±0.56)L][(P < 0.05)],TG[(1.97 ± 0.96),(1.54±0.55)] and LDL [(2.52 ± 0.44),(2.26±0.37)] were lower than the V1 [(2.77 ± 1.33),(3.09 ± 0.45)],P < 0.05.But,FEV1 and TC had no significant change,P > 0.05.3、At V2,V3,the daytime symptoms [(1.45 ± 0.60)/d,(1.40 ± 0.50)/d],night symptom [(1.55 ± 0.69)/d,(1.45 ± 0.52)/d],torin usage [(1.10 ± 0.77),(0.98 ±0.73)/d/d],and ACT score [(18.80 ±2.65),(20.70±3.18)] of the conventionalgroup were improved significantly than V1 [(1.95 ± 0.83)/d,(1.95 ± 0.76)/d,(1.65 ± 0.87)/d,(16.65±3.07)],P < 0.05.But the FEV1、FVC、TC、TG、LDL and serum leptin levels had no significant improvement,P > 0.05.4、At the end of V3,patients’ daily symptoms(1.26±0.44)/d,night symptom(1.30±0.47)/d,torin usage(0.65±0.60)/d,ACT score(22.60±2.39),FVC(2.87±0.47)L,TG(1.54 ± 0.55),LDL(2.26 ± 0.37),and serum leptin levels(11.23 ± 1.12)ug/L of the experimental group were improved significantly than the conventional group [(1.40±0.50)/d、(1.45±0.52)/d、(0.98±0.73)/d、(20.70±3.18)、(2.32±0.38)L、(2.70±1.31)、(3.13 ± 0.47)、(14.93 ± 1.47)ug/L],P < 0.05.But compared with the conventional group,FEV1 and TC had no significant difference,P > 0.05.5、There were 1 patients treated with emergency treatment and 1 patients with mild ALT in the experimental group;2 patients in the control group were treated with emergency treatment,and no patients had AST or ALT increased.The incidences of adverse reactions in the two groups were not statistically difference,P>0.05.ConclusionSimvastatin can safely improve clinical symptoms of adult obesity patients with asthma,increase forced vital capacity,reduce serum lipid level,reduce airway inflammation and emergency medical care.